HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Parmax Pharma Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Parmax Pharma Ltd Stock Comparison

Last Updated on: Apr 30, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1383 as of 30 Apr 13:07.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 27019 crore on March 2024 . This represents a CAGR of 35.97% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Dec '24 is ₹ 3418 crore as compare to the Sep '24 revenue of ₹ 3473 crore. This represent the decline of -1.57% The revenue of Parmax Pharma Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '24 is ₹ 631.36 crore as compare to the Sep '24 ebitda of ₹ 641.33 crore. This represent the decline of -1.55% The ebitda of Parmax Pharma Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 348.03 crore over 7 quarters. This represents a CAGR of 49.03% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 1.37 % on March 2024 . This represents a CAGR of -23.44% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.
  • The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland.

About Parmax Pharma Ltd

  • Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
  • The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
  • The Company then discontinued their business activities for few years due to various reasons.
  • Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharma's US arm set to launch generic Adderall tablets

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroampheta...

Read more

17 Apr 2025 08:04

News

Glenmark Pharmaceuticals allots 12,653 equity shares under ESOP

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the p...

Read more

17 Apr 2025 20:08

News

Glenmark USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphe...

Read more

16 Apr 2025 19:53

News

Glenmark Pharmaceuticals Ltd slips for fifth straight session

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quot...

Read more

11 Apr 2025 13:35

News

Glenmark Pharmaceuticals announces change in senior management

Glenmark Pharmaceuticals has appointed Anurag Mantri as President (Senior Management Perso...

Read more

07 Apr 2025 09:00

News

Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochlo...

Read more

01 Apr 2025 09:40

Parmax Pharma Ltd News Hub

News

Parmax Pharma to conduct board meeting

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 February ...

Read more

07 Feb 2025 15:55

News

Parmax Pharma to discuss results

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 November ...

Read more

07 Nov 2024 11:45

News

Parmax Pharma to conduct AGM

Parmax Pharma announced that the Annual General Meeting (AGM) of the company will be held ...

Read more

18 Sep 2024 16:46

News

Parmax Pharma to declare Quarterly Result

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 14 August 20...

Read more

09 Aug 2024 14:53

News

Parmax Pharma revises board meeting date

Parmax Pharma has revised the meeting of the Board of Directors which was scheduled to be ...

Read more

29 May 2024 12:10

News

Parmax Pharma schedules board meeting

Parmax Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2024 ...

Read more

24 May 2024 12:53

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Parmax Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Parmax Pharma Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 39,060 Cr while Market cap of Parmax Pharma Ltd is 15 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd?

As of April 30, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1384.2. On the other hand, Parmax Pharma Ltd stock price is INR ₹42.02.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions